BIO-PATH HOLDINGS INC (BPTH)

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). The company is headquartered in Bellaire, Texas and currently employs 10 full-time employees. The company went IPO on 2006-01-11. The company utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, BP1003, targets the STAT3 protein. Its modified product named BP1001-A, is its fourth drug candidate for treatment of solid tumors.

Company Info

BIO-PATH HOLDINGS INC

4710 Bellaire Blvd Ste 210

Bellaire TEXAS 77401

P: 18327421357

CEO: Peter H. Nielsen

Employees: 10

Website: https://www.biopathholdings.com/